
Data point towards clinical trials of a light-based keratitis therapy in humans.

Data point towards clinical trials of a light-based keratitis therapy in humans.

The Neurolens N3 gains EU MDR certification for Contoured Prism lens prescribing, with first European launches planned for 2027.

The non-invasive device, already available in Canada, Australia, and New Zealand, delivers low-level microcurrent through closed eyelids in 32-minute in-clinic sessions.

Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.

Cataract surgery is not neutral for the vitreous.

Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.

A simple stool test may reveal hidden bowel disease in patients whose only symptoms are in their eyes.

Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.

Artelac Ectoin improved tear-film stability and key dry-eye symptoms within 28 days

An association has been identified between primary open-angle glaucoma and erectile dysfunction.

Omur Ucakhan, MD, explains why artificial tears are not interchangeable and how dry eye phenotype should guide formulation choice.

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.

AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027.

Key takeaways on gene therapy, GA, sustained delivery and AI in Vienna

At EURETINA 2026, Mitrofanis Pavlidis, MD, PhD, explains how double-cutting probes, new pump technology and integrated visualisation reduced core vitrectomy time in 27-gauge surgery.

At EURETINA 2026, Paola Sasso, MD, and Antonio Baldascino, MD, discussed cataract surgery with the EyeMax Mono IOL followed by structured visual rehabilitation in patients with late-stage AMD.

Tunde Peto, MD, PhD, explains how ultra-widefield imaging showed that macular degeneration affects the peripheral retina, and why measuring both peripheral and central vision matters for patients’ daily function.

At EURETINA 2026, Jordi Monés, MD, PhD, outlined the rationale for gene-agnostic optogenetic therapy MCO-010 to restore vision in Stargardt disease and geographic atrophy.

Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.

At EURETINA 2026, David Steel reviewed registry evidence on gas and silicone oil tamponades for retinal detachment repair and outlined novel tamponade agents in his Kreissig Award Lecture.

At EURETINA 2026, Roger Goldberg, MD, MBA, explains why EYP-1901 missed LUGANO's primary endpoint despite matched anatomy, clean safety and a 42% cut in treatment burden.

Ritesh Narula, MBBS, MS, discusses phase 1 and early phase 2 results of the Eyestem subretinal stem cell study in geographic atrophy, including an 11-letter mean visual acuity gain maintained at 18 months.

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with readouts expected over the next 12 months.

Ashish Sharma, MD, on what real-world data show about switching and long-term outcomes with retinal biosimilars.

João Pedro Marques, MD, MSc, PhD, FEBOphth, discusses the IRD-PT, a web-based Portuguese registry of roughly 2,400 patients with inherited retinal diseases that supports research and identifies patients for clinical trials.

At EURETINA 2026, Elon van Dijk, MD, PhD, FEBOphth, reviewed trial evidence favouring half-dose PDT over micropulse laser and eplerenone for central serous chorioretinopathy.

Paul Nderitu, MBChB, MPhil, MBCS, FRCOphth, PhD, gives an update at EURETINA 2026 on Global RETFound, a foundation model being built with 108 partners from more than 40 countries

Katherine Talcott, MD, discusses phase 2 VERONA results showing EYP-1901 plus aflibercept reduced supplemental treatment needs in DME, with early vision and anatomy gains and no significant safety signals.

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews 2-year SPECTRA data on 4D-150 gene therapy for DMO and the phase 3 4SIGHT trial comparing it with aflibercept.